Merck and Pfizer Provide Update on Avelumab inPlatinum-Resistant
Refractory Ovarian Cancer
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for
US, Canada and UK-based media
Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III
JAVELIN Ovarian 200 trial evaluating avelumab* alone or in
combination with pegylated liposomal doxorubicin (PLD), a type of
chemotherapy, compared with PLD did not meet the prespecified primary
endpoints of overall survival (OS) or progression-free survival (PFS)
in patients with platinum-resistant or -refractory!-->!-->!-->…